Mirum Pharmaceuticals vs Nurix Therapeutics
MIRM and NRIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MIRM and NRIX compare
Mirum Pharmaceuticals is the larger company, worth 3.6 times as much as Nurix Therapeutics ($6.1B against $1.7B).
Nurix Therapeutics grew revenue faster over the last twelve months (739% versus 44.0% for Mirum Pharmaceuticals).
Nurix Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.0% compared with −139% at Mirum Pharmaceuticals.
Nurix Therapeutics scores higher on the StockData Score (15 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MIRM | NRIX |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | $1.7B |
| Share price | $93.99 | $15.48 |
| Change, 1 year | 32.8% | 27.2% |
| Change, 5 years | 499% | −50.6% |
| Beta (5Y) | 0.63 | 1.46 |
| Employees | 372 | 317 |
| StockData Score | ||
| Total score | 5 | 15 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 6.7× |
| P/S | 9.9× | 2.4× (better) |
| P/B | – | 1.7× |
| EV/EBITDA | – | 2.0× |
| P/FCF | – | 4.6× |
| FCF yield | −3.7% | 21.9% (better) |
| Fair value | – | $57.66 |
| Margin of safety | – | 73.2% |
| Growth | ||
| Revenue growth (TTM) | 44.0% | 739% (better) |
| Revenue growth, 5Y average | – | 36.3% |
| Profitability | ||
| Operating margin | −135% | 41.3% (better) |
| Net margin | −139% | 42.0% (better) |
| FCF margin | −37.0% | 52.7% (better) |
| Return on equity | −703% | 44.0% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −62.1× | – |
| Current ratio | 2.86 | 8.44 (better) |
| Altman Z-score | −0.14 | 6.10 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −1.1% |
| Shareholder yield | 0.00% (better) | −1.1% |
| Ownership | ||
| Held by institutions | 110% | 107% |
| Held by insiders | 9.2% | 3.2% |
| Insider net buying, 12 months | −$31.5M | −$5.2M (better) |
| Short interest, % of float | 11.1% | 17.9% |
Go deeper
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
- NRIX stock overview
- NRIX income statement
- NRIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.